Skip to main content
TrendingNews.today
World News
S&P 500 5,142.30 ▲ +0.87%|NASDAQ 16,284.75 ▲ +1.12%|DOW 38,972.10 ▼ -0.23%|AAPL $192.45 ▲ +1.80%|TSLA $241.80 ▼ -2.10%|AMZN $178.92 ▲ +0.54%|GOOGL $141.20 ▲ +0.32%|MSFT $415.60 ▼ -0.15%|
S&P 500 5,142.30 ▲ +0.87%|NASDAQ 16,284.75 ▲ +1.12%|DOW 38,972.10 ▼ -0.23%|AAPL $192.45 ▲ +1.80%|TSLA $241.80 ▼ -2.10%|AMZN $178.92 ▲ +0.54%|GOOGL $141.20 ▲ +0.32%|MSFT $415.60 ▼ -0.15%|
As of Mar 26
ScienceUnited States1 sourcesNeutral

Corcept’s Lifyorli wins early FDA approval for ovarian cancer

The U.S. FDA approved Corcept Therapeutics Inc.’s oral, selective glucocorticoid receptor antagonist relacorilant nearly four months ahead of schedule for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.

KC
karen carey
via Bioworld
ShareRead original

Read the full article at Bioworld →

Corcept’s Lifyorli wins early FDA approval for ovarian cancer

Source Verification

Corroboration Score: 1

This story was independently reported by 1 sources. Click any source to read the original article.

Bioworld
Bioworld
NewsDataUS

Comments

0 comments
Be respectful and constructive.
Loading comments...
Previous
World Food Prize goes to food safety scientist for preventing millions of cases of foodborne illness
Next
Male Hormones Linked to Aggressive Rare Pediatric Brain Tumor

Related Articles

Extreme global climate outcomes are possible even at 2°C warming, study warnsScience
Extreme global climate outcomes are possible even at 2°C warming, study warns
Phys.org-13h ago-1 sources
Merck adds Terns’ promising CML drug in $6.7B buyoutScience
Merck adds Terns’ promising CML drug in $6.7B buyout
Bioworld-13h ago-1 sources
PKU ballyhoo averting Street’s gaze from Maze phase II AMKD win?Science
PKU ballyhoo averting Street’s gaze from Maze phase II AMKD win?
Bioworld-13h ago-1 sources